Redmile Group’s Xenon Pharmaceuticals XENE Stock Holding History

Redmile Group’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$15.3M	Buy	262,674 +128,792	+96%	+$5.93M	1.01%	17
2025 Q4	$6M	Buy	+133,882	New	+$5.62M	0.44%	29
2023 Q4	–	Sell	-419,568	Closed	-$14.3M	–	73
2023 Q3	$14.3M	Sell	419,568 -700,908	-63%	-$26.2M	0.68%	35
2023 Q2	$43.1M	Sell	1,120,476 -205,356	-15%	-$8.16M	1.66%	16
2023 Q1	$47.5M	Sell	1,325,832 -1,034,582	-44%	-$38.2M	2.06%	17
2022 Q4	$93.1M	Sell	2,360,414 -10,200	-0.4%	-$371K	3.81%	7
2022 Q3	$85.6M	Buy	2,370,614 +731,270	+45%	+$26.3M	3.32%	6
2022 Q2	$49.9M	Buy	+1,639,344	New	+$49.6M	1.9%	16

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Redmile Group's XENE Position: Q1 2026 in Review

Redmile Group increased its Xenon Pharmaceuticals (XENE) stake by 96% in Q1 2026, buying an estimated $5.93M and bringing the position to 262,674 shares worth $15.3M. The position accounts for 1.01% of the portfolio, ranked #17.

Redmile Group first reported a position in XENE in Q2 2022 and has held it in 8 quarters since. The position peaked at $93.1M in Q4 2022. 290 funds tracked by Wall St. Rank hold XENE as of Q1 2026.

Redmile Group held 262,674 shares of Xenon Pharmaceuticals worth $15.3M as of Q1 2026.
Redmile Group bought 128,792 Xenon Pharmaceuticals shares in Q1 2026, an estimated $5.93M.
Xenon Pharmaceuticals made up 1.01% of Redmile Group's portfolio in Q1 2026, its #17 holding.
Redmile Group first reported a position in Xenon Pharmaceuticals in Q2 2022 and has held it in 8 quarters since.
Redmile Group's Xenon Pharmaceuticals position peaked at $93.1M in Q4 2022.
290 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q1 2026.

Based on Redmile Group's 13F filing for Q1 2026, filed 15 May 2026.